LRRK2 and Parkinson disease: In these reports, dopaminergic neurons differentiated from induced pluripotent stem cells (iPSCs) prepared from PD patients harboring the G2019S LRRK2 mutation consistently showed increased amounts of cytoplasmic α-synuclein, presumably due to posttranslational alterations [53,54,55,56].